Bladder Cancer Trial, Recruiting NCT06986304 Sponsor: Duke University Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06986304
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years of age.
  • People who have been diagnosed with bladder cancer (confirmed by tissue testing) for which their treating doctor has recommended surgical removal of the bladder — for example, muscle-invasive bladder cancer, or high-risk non-muscle-invasive bladder cancer that has not responded to BCG treatment or has concerning features under the microscope.

Who may not be able to join:

  • People with a known or suspected allergy to sulfur hexafluoride lipid microspheres or any of their ingredients, such as polyethylene glycol (PEG).
  • People who are currently pregnant or breastfeeding.
  • People who do not wish to take part in the study.
  • People who have had a serious allergic reaction to a COVID-19 vaccine.
  • People whose health is currently unstable — for example, those currently admitted to hospital, in an intensive care unit, or living with serious heart conditions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Abern, M.D., Duke University

Phone: 919-684-5057

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
28 October 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Presence and stage of residual bladder cancer at the time of RC.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov